

Published in final edited form as:

*Schizophr Bull Open*. ; 4(1): . doi:10.1093/schizbullopen/sgad015.

## Auditory Cortex Thickness Is Associated With N100 Amplitude in Schizophrenia Spectrum Disorders

Nora Berz Slapø<sup>\*1</sup>, Stener Nerland<sup>1,2</sup>, Kjetil Nordbø Jørgensen<sup>1,3</sup>, Lynn Mørch-Johnsen<sup>4,5,6</sup>, Johanne Hagen Pettersen<sup>7</sup>, Daniel Roelfs<sup>1</sup>, Nadine Parker<sup>1</sup>, Mathias Valstad<sup>1,7</sup>, Atle Pentz<sup>1</sup>, Clara M. F. Timpe<sup>1,8</sup>, Geneviève Richard<sup>1</sup>, Dani Beck<sup>1,2</sup>, Maren C. Frogner Werner<sup>1</sup>, Trine Vik Lagerberg<sup>2</sup>, Ingrid Melle<sup>1</sup>, Ingrid Agartz<sup>3,4,9</sup>, Lars T. Westlye<sup>1,8</sup>, Nils Eiel Steen<sup>1</sup>, Ole A. Andreassen<sup>1,4</sup>, Torgeir Moberget<sup>1,10</sup>, Torbjørn Elvsåshagen<sup>1,11</sup>, Erik G. Jönsson<sup>1,8</sup>

<sup>1</sup>Department of medicine, NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

<sup>2</sup>Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway

<sup>3</sup>Department of Psychiatry, Telemark Hospital, Skien, Norway

<sup>4</sup>NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

<sup>5</sup>Department of Psychiatry, Østfold Hospital, Grålum, Norway

<sup>6</sup>Department of Clinical Research, Østfold Hospital, Grålum, Norway

<sup>7</sup>Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway

<sup>8</sup>Department of Psychology, University of Oslo, Oslo, Norway

<sup>9</sup>Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Sciences, Stockholm Region, Sweden

<sup>10</sup>Department of Behavioral Sciences, Faculty of Health Sciences, Oslo Metropolitan University, OsloMet, Oslo, Norway

<sup>11</sup>Department of Neurology, Oslo University Hospital, Oslo, Norway

### Abstract

**Background and Hypothesis**—The auditory cortex (AC) may play a central role in the pathophysiology of schizophrenia and auditory hallucinations (AH). Previous schizophrenia studies report thinner AC and impaired AC function, as indicated by decreased N100 amplitude of the auditory evoked potential. However, whether these structural and functional alterations link to AH in schizophrenia remain poorly understood.

---

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

\*To whom correspondence should be addressed; Norwegian Centre for Mental Disorders Research, Oslo University Hospital, PO Box 4956 Nydalen, Norway; tel: 0047 92086435; [n.b.slapo@medisin.uio.no](mailto:n.b.slapo@medisin.uio.no).

**Study Design**—Patients with a schizophrenia spectrum disorder (SCZ<sub>spect</sub>), including patients with a lifetime experience of AH (AH+), without (AH–), and healthy controls underwent magnetic resonance imaging (39 SCZ<sub>spect</sub>, 22 AH+, 17 AH–, and 146 HC) and electroencephalography (33 SCZ<sub>spect</sub>, 17 AH+, 16 AH–, and 144 HC). Cortical thickness of the primary (AC1, Heschl’s gyrus) and secondary (AC2, Heschl’s sulcus, and the planum temporale) AC was compared between SCZ<sub>spect</sub> and controls and between AH+, AH–, and controls. To examine if the association between AC thickness and N100 amplitude differed between groups, we used regression models with interaction terms.

**Study Results**—N100 amplitude was nominally smaller in SCZ<sub>spect</sub> ( $P = .03$ ,  $d = 0.42$ ) and in AH– ( $P = .020$ ,  $d = 0.61$ ), while AC2 was nominally thinner in AH+ ( $P = .02$ ,  $d = 0.53$ ) compared with controls. AC1 thickness was positively associated with N100 amplitude in SCZ<sub>spect</sub> ( $t = 2.56$ ,  $P = .016$ ) and AH– ( $t = 3.18$ ,  $P = .008$ ), while AC2 thickness was positively associated with N100 amplitude in SCZ<sub>spect</sub> ( $t = 2.37$ ,  $P = .024$ ) and in AH+ ( $t = 2.68$ ,  $P = .019$ ).

**Conclusions**—The novel findings of positive associations between AC thickness and N100 amplitude in SCZ<sub>spect</sub>, suggest that a common neural substrate may underlie AC thickness and N100 amplitude alterations.

### Keywords

psychosis; auditory hallucinations; MRI; brain structure; EEG; event-related potentials; brain function

### Introduction

Schizophrenia spectrum disorders are severe mental disorders affecting approximately 1.0% of the general population.<sup>1,2</sup> Auditory hallucinations (AH) are cardinal symptoms in schizophrenia, affecting more than 70% of patients.<sup>3–5</sup> While the exact pathophysiological mechanisms behind schizophrenia and AH remain elusive, evidence from structural and functional neuroimaging studies points toward the involvement of the auditory cortex (AC).<sup>3,6–8</sup> Magnetic resonance imaging (MRI) studies show altered AC structure in schizophrenia,<sup>9–12</sup> including smaller AC volume<sup>13–15</sup> and AC thickness.<sup>16–21</sup> More specifically, reduced thickness was found in Heschl’s gyrus (HG)<sup>17–19,22</sup> and in the planum temporale (PT)<sup>17,22</sup> in these patients. Studies in schizophrenia indicate an association between altered structure in the AC and AH,<sup>16,23–25</sup> including reduced thickness in the left AC,<sup>17,19,22</sup> in the right HG<sup>18,19</sup> and in the superior temporal gyrus (STG),<sup>16</sup> including the PT.<sup>17,22</sup> Further, studies report an association between volume loss in the STG, including the HG (mostly the left side) and severity of AH in schizophrenia.<sup>24–26</sup> Thus, it is possible that the aforementioned cortical thinning reflects underlying disease mechanisms that result in disturbed function of the temporal cortex, including the AC, and lead to vulnerability toward AH.<sup>16</sup> Supporting these in vivo findings, postmortem studies have reported morphological alterations of neurons in the AC of patients with schizophrenia,<sup>27</sup> including reduced neuronal size and synaptic density of cortical layer 3 pyramidal cells.<sup>28,29</sup> These findings indicate decreased number of dendritic spines<sup>30,31</sup> and density of axon terminals<sup>32</sup> in the AC in schizophrenia compared with healthy subjects. At the functional level, auditory processing deficits such as an impaired ability to distinguish between tones, have been

reported in schizophrenia.<sup>33</sup> Furthermore, electroencephalography (EEG) studies show attenuated auditory mismatch negativity (MMN) responses in schizophrenia, indicating impaired auditory processing.<sup>34–37</sup> Moreover, the amplitude of the N100 component of the auditory evoked potential (AEP), an EEG signal thought to mainly reflect function in the AC,<sup>38–42</sup> is reduced in schizophrenia.<sup>33,43–48</sup> In addition, the N100 latency has been shown to be altered in patients with schizophrenia.<sup>49</sup> Studies using functional MRI and position emission tomography report activation of the temporal cortex,<sup>50,51</sup> including activation of the HG<sup>8,23,52–54</sup> and the PT<sup>23,50,54,55</sup> during active AH. In addition, sMRI studies reveal associations between gray matter in the HG and auditory MMN in schizophrenia.<sup>56,57</sup> Hence, since auditory MMN and tone discrimination are thought to depend on the integrity of cells in layers 1–3 of the HG,<sup>34</sup> these findings point toward a direct relationship between gray matter HG volume, neuronal alterations in the HG, and auditory processing deficits in schizophrenia.<sup>58,59</sup> Liem et al reported an inverted association between thickness in the AC and N100 amplitude in a small sample ( $n = 27$ ) of HC.<sup>60</sup> No previous study has investigated this relationship in patients with schizophrenia. However, lower N100 amplitude has been reported in a small sample of patients with schizophrenia during active AH compared with no active AH in the same patients.<sup>61</sup> Whether cortical thickness and N100 amplitude relate to each other and to AH in schizophrenia remain unclear. To date, no study has investigated this relationship.

In the present study, we (1) investigated if AC thickness and N100 amplitude in patients with schizophrenia spectrum disorders ( $SCZ_{spect}$ ) are different from healthy controls (HC), and assessed the relationship between AC thickness and N100 amplitude across both  $SCZ_{spect}$  and HC. (2) We investigated differences in AC thickness and N100 amplitude between  $SCZ_{spect}$  patients with a lifetime history of AH (AH+), without AH (AH–), and HC, and examined the AC thickness-N100 amplitude association within AH+ and AH. Our primary hypothesis was that patients with  $SCZ_{spect}$  have thinner AC and smaller N100 amplitude compared with HC and that AC thickness and N100 amplitude would be positively associated among patients and controls. Our secondary hypothesis was that thinner AC and lower N100 amplitude in  $SCZ_{spect}$  are driven by the AH+ group and that AH– are more similar to HC in AC thickness, N100 amplitude, and the structure-function relationship.

## Methods

### Participants

Participants with a DSM-IV diagnosis within  $SCZ_{spect}$  and HC were included from the ongoing Thematically Organized Psychosis (TOP) research study. HC were randomly drawn from the national population register within the same catchment area and asked to participate in the study. The study was approved by the Regional Committees for Medical and Health Research Ethics of South-Eastern Norway, and was conducted in accordance with the Helsinki declaration. Participants provided written informed consent. Participants with a history of head trauma resulting in loss of consciousness, an IQ <70, or somatic or neurological disorders believed to influence brain function, were excluded from the study. In addition, HC with a history of mental disorders and/or severe mental disorders in first degree

relatives or a history of alcohol- and substance abuse or dependence were excluded. In total, 453 participants (51 SCZ<sub>spect</sub> and 402 HC) had MRI and EEG data available. We excluded participants with clinically relevant incidental findings on their MRI scan (7 SCZ<sub>spect</sub> and 20 HC), with poor event-related potential (ERP) signals on visual inspection (74 participants, including 11 SCZ<sub>spect</sub> and 63 HC), and with a time interval between MRI scanning and EEG recording of more than 12 months (1 HC). Since our healthy controls were significantly older than patients with SCZ<sub>spect</sub>, we matched controls to patients at the group level. In the final age-matched sample, 185 participants had good MRI data quality, including 39 patients with SCZ<sub>spect</sub> (schizophrenia [ $n = 23$ ], schizophreniform [ $n = 1$ ], schizoaffective [ $n = 1$ ], and psychosis not otherwise specified [ $n = 14$ ]) and 146 HC. Further, 177 participants had good EEG and MRI data quality, including 33 patients with SCZ<sub>spect</sub> (schizophrenia [ $n = 21$ ], schizophreniform [ $n = 1$ ], and psychosis not otherwise specified [ $n = 11$ ]) and 144 HC. In this sample, MRI, EEG, and clinical investigations were performed between 2015 and 2019 with a median time interval between examinations of 12 days (0–337 days; interquartile range = 32 days).

### Clinical Assessment

Trained clinical psychologists or physicians diagnosed patients according to the Structural Clinical Interview for DSM-IV (SCID-I).<sup>62</sup> We defined age of onset as age at first positive psychotic symptoms (verified by SCID-I) and the duration of illness (DOI) as years from age of onset to age at MRI. To assess psychosocial functioning we used the split version of the Global Assessment of Function (GAF-S and GAF-F) scale.<sup>63</sup> Current symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS) interview.<sup>64</sup> For each patient, the current dosage of antipsychotic medication(s) was converted into defined daily dose (DDD), where 1 DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults ([www.whocc.no/atc\\_ddd\\_index/](http://www.whocc.no/atc_ddd_index/)).

### Auditory Hallucinations

Lifetime presence of AH was determined using the B16 item from the SCID-I interview.<sup>62</sup> Patients with score of 3 (threshold or true) were determined as patients with a lifetime history of AH (AH+), while patients with a score of 1 (absent or false) and 2 (subthreshold) were determined as patients without a lifetime history of AH (AH-). In our final sample of patient with good quality MRI and EEG data available ( $n = 33$ ), 8 participants had a SCID-B16 score of 1, 8 had score of 2, and 17 had a score of 3.

### MRI Acquisition and Processing

MRI scanning was performed with a Discovery MR750 3T scanner (General Electric Medical Systems, Milwaukee, USA) equipped with a 32-channel head coil at the Regional Core Facility in Translational MRI Neuroimaging at the Oslo University Hospital. T1-weighted images were acquired with a gradient echo inversion recovery sequence (BRAVO), with voxel size of  $1 \times 1 \times 1$  mm, inversion time 450 ms, echo time 3.18 ms, repetition time 8.16 ms, flip angle  $12^\circ$ , acceleration factor 2, and an acquisition time of 4:43. To correct for intensity nonuniformities, Phased array Uniformity Enhancement was enabled. T1-weighted MR images were processed with recon-all in FreeSurfer version 6.0.0.<sup>65</sup> This processing pipeline uses intensity information to reconstruct the inner (ie, the gray/white

matter boundary) and outer (ie, the gray matter/cerebrospinal fluid boundary) surfaces of the cerebral cortex which are used to compute cortical thickness and surface area. Quality control and editing were conducted by trained research assistants following standard FreeSurfer procedures. Cortical thickness and surface area were extracted from 3 bilateral regions of interest in the Destrieux atlas<sup>66</sup>: The anterior transverse temporal gyrus of Heschl (HG), the transverse temporal sulcus (Heschl's sulcus: HS), and the temporal plane of the STG (PT). Cortical labels were visually inspected to ensure correct placement. No subjects were excluded due to poor parcellation. For the main analyses, we defined 2 main regions of interest; the HG, referred to as the AC1 in the manuscript, and the combined HS-PT, referred to as AC2 in the manuscript. Cortical thickness was calculated as an area-weighted mean across hemispheres and subregions, while surface area was calculated as a simple sum. See supplementary note 1 for details on parcellation of the AC and supplementary note 2 for details on how we calculated thickness and surface area. See supplementary figures 1 and 2 for illustrations of the AC1 (HG) and AC2 (HS-PT) regions of interest.

### **AEPs Obtained From the Prepulse-Inhibition Paradigm**

AEPs were elicited during a prepulse-inhibition (PPI) task. During the PPI paradigm, the participant focuses on a red dot in the middle of a computer-screen while exposed to a background noise at 70 dB for 3 minutes (to allow for habituation) followed by 3 auditory startle stimuli (40 ms white noise with near instantaneous rise/fall times) presented at 115 dB. After this initial assessment of the startle response, the main experimental block consisted of 48 startle stimuli presented either alone (12 trials) or following a weaker prepulse stimulus (20 ms white noise with near instantaneous rise/fall times presented at 85 dB) at intervals of either 30, 60, or 120 ms. The main experimental block also contained 12 prepulse alone trials, where only the prepulse stimulus was presented. Finally, after the main experimental block, 3 auditory startle stimuli were again presented, in order to measure habituation to the startle stimulus. The average interstimulus interval (ISI) was approximately 9 seconds, which in combination with the relatively strong stimulus intensity, elicits a strong AEP.<sup>67</sup> The current article focuses on AEPs elicited by the prepulse stimulus, since this typically does not elicit a muscular startle response. Prior to the EEG examination, hearing was assessed at 20 and 40 dB. All participants that were included in the current study were able to hear the auditory stimuli at <40 dB. Supplementary figure 3 shows the timeline of the entire EEG session.

### **EEG Acquisition and Processing**

We recorded EEG data at 2048 Hz from 64 Ag-AgCl scalp electrodes arranged according to the international 10-5 system using a BioSemi ActiveTwo amplifier. In addition, 4 external electrodes recorded lateral and vertical eye movements and 2 recorded the heart rhythm (electrocardiography). The Biosemi system uses a common mode sense with a driven right leg electrode in order to minimize common mode voltages. All offline EEG processing was conducted using the MATLAB-based EEGLAB toolbox.<sup>68</sup> After downsampling to 512 Hz, we removed noisy channels using the PREP Pipeline algorithms with default setting.<sup>69</sup> We referenced remaining channels to the average of all good channels before we interpolated removed channels from surrounding channel potentials. Next, we re-referenced all channels to the new common average obtained after interpolation of bad channels. After average

referencing, we removed the mean offset from all channels and applied a high pass filter of 1 Hz. The Trimoutlier eeglab plugin (<https://scn.ucsd.edu/wiki/TrimOutlier>) identifies and remove sections of bad data (defined as  $\pm 500$  ms around any data point exceeding  $500 \mu\text{V}$  across the 64 scalp channels) in the continuous EEG files. Next, independent component analysis (ICA) and automated detection of eye-blink artifacts (ICLabel)<sup>70</sup> were used to automatically identify EEG artifacts such as eye blinks, line noise, muscle movements, heart noise, and channel noise. All independent components were also visually inspected, before rejection of components with  $< 50\%$  chance of originating from brain activity (assigned by ICLabel). Cleaned EEG data were next low pass filtered to 40 Hz and separate epochs were extracted for each stimulus event with the time window of  $-200$  to  $700$  ms.

Finally, epoched data were baseline corrected from  $-100$  to  $0$  ms. Prior to extraction of ERP voltages, the ERPs were re-referenced to linked mastoids to capture both the negative (on centro-frontal electrodes) and positive (on inferior temporal and posterior electrodes) polarity of the auditory ERP (which inverts over the Sylvian fissure). Trials containing amplitudes exceeding  $\pm 100 \mu\text{V}$  were excluded prior to averaging. All 12 prepulse alone trials were included. Peak latency and amplitude for the N100 component were defined as the minimal amplitude within a time window from  $50$  to  $200$  ms after stimulus onset and extracted from channel Cz. In our main analyses, we focused on the N100 amplitude from the Cz electrode. However, we also examined N100 latency. AEPs of individual participants were visually inspected in EEGLAB to ensure that the time windows used in the scripts were correct and that they accurately identified peaks and latencies (between  $50$  and  $200$  ms). After visual inspection of individual AEPs, we concluded that for the majority of subjects 12 prepulse alone trials were indeed sufficient for eliciting robust AEPs. Further, after visual inspection of individual AEPs, we excluded 74 participants where the peak N100 amplitude (the most negative peak) was outside of the latency range of  $50$ – $200$  ms. N100 amplitude, ie, generated at  $85$  dB and a longer ISI will elicit a higher amplitude than N100 generated at lower dB and shorter ISI.<sup>71</sup> Visual inspection revealed that N100 amplitudes were negative for all participants (from  $-3.18$  to  $-43.62 \mu\text{V}$ ). In order to ease interpretation, we multiplied all negative values with  $-1$ , giving N100 amplitudes of  $3.18$ – $43.62 \mu\text{V}$ , so that a higher number reflects a more prominent N100. Figure 1 illustrates individual AEPs from 12 randomly selected patients with SCZ<sub>spect</sub>, including 6 AH+ and 6 AH-. Figure 2 illustrates individual AEPs from 24 randomly selected HCs. Figure 3 illustrates mean and individual AEPs from all SCZ<sub>spect</sub>, HC, AH+, and AH-.

## Statistical Analyses

Statistical analyses were conducted using R version 3.6 (<https://www.r-project.org>) and figures were created using the ggplot2 package in R.<sup>72</sup> Group differences in demographics and clinical variables in the sample of patients and controls with EEG and MRI data ( $n = 177$ ), as provided in table 1, were calculated using the  $t$ -test for continuous variables and the chi-squared test for categorical variables.

To compare AC1 thickness and AC2 thickness between SCZ<sub>spect</sub> ( $n = 39$ ) and HC ( $n = 146$ ), we performed separate analysis of covariance (ANCOVA). First, AC1 thickness was set as outcome variable, diagnostic group and sex as factors, and age as a covariate. Then, AC2

thickness was set as outcome variable, diagnostic group and sex as factors, and age as a covariate. To compare N100 amplitude (and N100 latency) between SCZ<sub>spect</sub> ( $n = 33$ ) and HC ( $n = 144$ ), we performed ANCOVA, where N100 amplitude (or N100 latency) was set as outcome variable, diagnostic group and sex as factors, and age as a covariate. Cohen's  $d$  for group comparisons was calculated from differences in predicted means.<sup>73</sup>

To test for associations between AC thickness and N100 amplitude, we fitted linear regression models, for SCZ<sub>spect</sub> ( $n = 33$ ) and HC ( $n = 144$ ) separately, with AC1 or AC2 thickness as dependent variables with age, sex, and N100 amplitude as independent variables. To examine whether the AC-N100 associations differed between diagnostic groups (SCZ<sub>spect</sub> and HC), we ran regression models with AC (AC1 and AC2) thickness as the dependent variable and age, sex, diagnosis, in addition to the interaction term (diagnosis  $\times$  N100 amplitude) as independent variables. We ran this model in the combined sample ( $n = 177$ ) of SCZ<sub>spect</sub> ( $n = 33$ ) and HC ( $n = 144$ ).

To compare AC1 thickness and AC2 thickness between AH+ ( $n = 22$ ), AH- ( $n = 17$ ), and HC ( $n = 146$ ), we ran separate ANCOVA where AC (AC1 or AC2) thickness was set as outcome variable, AH status (AH+, AH-, or HC) and sex as factors, and age as a covariate. To compare N100 amplitude (and N100 latency) between AH+ ( $n = 17$ ), AH- ( $n = 16$ ), and HC ( $n = 144$ ), we ran ANCOVA where N100 amplitude (or N100 latency) was set as outcome variable, AH status and sex as factors, and age as a covariate. Cohen's  $d$  for group comparisons was calculated from differences in predicted means.<sup>73</sup>

To test for associations between AC thickness and N100 amplitude in AH+ ( $n = 17$ ), AH- ( $n = 16$ ), and HC ( $n = 144$ ) we fitted linear regression models, for AH+, AH-, and HC separately, with AC thickness as dependent variables with age, sex, and N100 amplitude as independent variables. To examine whether the AC-N100 associations differed between AH+, AH-, and HC, we ran regression models with AC thickness as the dependent variable and age, sex, AH status (AH+, AH-, or HC) in addition to the interaction term (AH status  $\times$  N100 amplitude) as independent variables. HC was set as the reference for AH status. We ran this model in the combined sample ( $n = 177$ ) of patients and controls. For the ANCOVA analyses, a  $P$ -value  $< .017$  was considered significant (0.05/3). For the linear regression analyses, a  $P$ -value  $< .025$  was considered significant (0.05/2).

In addition to our main analyses, we ran supplementary analyses testing for effects of age, sex, and N100 amplitude on AC thickness. In addition, we ran supplementary analysis on AC thickness for each hemisphere separately, for HS and PT thickness separately and for AC surface area. Further, we performed Pearson correlation analysis between AC thickness and N100 amplitude and examined for associations with DOI. Further, we examined association between N100 latency and thickness in AC and compared mean N100 amplitude and AC thickness between patients with a diagnosis of schizophrenia and patients with the other SCZ<sub>spect</sub> disorders.

## Results

### Demographics and Clinical Data

There were no significant differences in age or sex distribution between SCZ<sub>spect</sub> and HC. Further, there were no differences between AH+ and HC, between AH- and HC, or between AH+ and AH-.

### AC Thickness and N100 Amplitude in SCZ<sub>spect</sub> and HC

N100 amplitude was nominally smaller in SCZ<sub>spect</sub> compared with HC ( $P$ -value ( $P$ ) = 0.03, Cohen's  $d$  ( $d$ ) = 0.42) (table 2). N100 latency did not differ ( $P$  = .33,  $d$  = 0.19) between SCZ<sub>spect</sub> (mean N100 latency [in ms] = 127.98, standard error of the mean [SE] = 2.79, 95% confidence interval [CI] = 122.47–133.49) and HC (mean N100 latency [in ms] = 124.96, SE = 1.33, CI = 122.34–127.58). In SCZ<sub>spect</sub>, AC (AC1 and AC2) thickness was positively associated with N100 amplitude (AC1-N100:  $P$  = .016,  $t$  = 2.56; AC2-N100:  $P$  = .024,  $t$  = 2.37), ie, patients with SCZ<sub>spect</sub> with thinner AC have smaller (less negative) N100 amplitude. In HC, we found no significant AC-N100 associations. Results are shown in figure 4. Results from the regression models with interaction terms (diagnosis  $\times$  N100) confirmed that the association between AC2 thickness and N100 amplitude differed between diagnostic groups (SCZ<sub>spect</sub> and HC) (estimate [est] = 0.01, standard error [se] = 0.003,  $t$ -value ( $t$ ) = 2.30,  $P$  = .020). The AC1-N100 association was nominally different between diagnostic groups (est = 0.01, se = 0.003,  $t$  = 1.95,  $P$  = .05).

### AC Thickness and N100 Amplitude in AH+ and AH-

Compared with controls, AH+ had nominally thinner AC2 ( $P$  = .020,  $d$  = 0.53), while AH- had nominally smaller (less negative) N100 amplitude compared ( $P$  = .020,  $d$  = 0.61). Results are shown in table 3.

Mean N100 latency did not differ between AH+ (mean N100 latency [in ms] = 127.46, SE = 3.88, CI = 119.80–135.12) and HC (mean N100 latency [in ms] = 124.96, SE = 1.33, CI = 122.33–127.59) ( $P$  = .54,  $d$  = 0.16) between AH- (mean N100 latency [in ms] = 128.54, SE = 4.00, CI = 120.63–136.44) and HC ( $P$  = .40,  $d$  = 0.22) or between AH+ and AH- ( $P$  = .85,  $d$  = 0.07). AC2 thickness was positively associated with N100 amplitude ( $P$  = .019,  $t$  = 2.68), while AC1 thickness was at nominally positively associated with N100 amplitude ( $P$  = .026,  $t$  = 2.52) in AH+. These findings suggest that AH+ with thinner AC2 have smaller (less negative) N100 amplitude. In AH-, AC1 thickness was positively associated with N100 amplitude ( $P$  = .008,  $t$  = 3.18), suggesting that AH- with thinner AC1 have smaller (less negative) N100 amplitude. Results are shown in figure 5. Further, the AC1-N100 (est = 0.02, se = 0.01,  $t$  = 2.73,  $P$  = .007) and the AC2-N100 (est = 0.013, se = 0.0055,  $t$  = 2.386,  $P$  = .018) associations differed between AH- and HC. The AC-N100 association did not differ between AH+ and HC (AC1-N100: est = 0.004, se = 0.004,  $t$  = 1.12,  $P$  = .26; AC2-N100: est = 0.01, se = 0.003,  $t$  = 1.79,  $P$  = .07) or between AH+ and AH- (AC1-N100: est = 0.02, se = 0.01,  $t$  = 2.18,  $P$  = .04; AC2-N100: est = 0.01, se = 0.01,  $t$  = 1.23,  $P$  = .231). Results were unchanged when including DOI as a covariate (supplementary analysis 6).



In addition to our main results, of interest, the PT was significantly thinner in AH+ (supplementary table 8) and nominally thinner in SCZ<sub>spect</sub> (supplementary table 6) compared with HC. Further, in SCZ<sub>spect</sub>, HS, and PT thickness were nominally positively associated with N100 amplitude (supplementary table 7). In AH+, HS thickness was significantly positively associated with N100 amplitude, while PT thickness was nominally positively associated with N100 amplitude (supplementary table 9). Pearson correlation analyses confirmed strong correlations between AC thickness and N100 amplitude in SCZ<sub>spect</sub> and in AH+. Pearson correlation test confirmed that the AC thickness-N100 amplitude correlations differed between SCZ<sub>spect</sub> and HC and between AH+ and HC. See supplementary material for results from all supplementary analyses.

## Discussion

The current study yielded 3 main findings. First, N100 amplitude was nominally smaller in SCZ<sub>spect</sub> and in AH- compared with HC. Second, AC2 was nominally thinner in SCZ<sub>spect</sub> and AH+ compared with HC. Third, we discovered positive associations between AC thickness and N100 amplitude in SCZ<sub>spect</sub>, but not in HC. More specifically, we found positive association between AC1/AC2 thickness and N100 amplitude in SCZ<sub>spect</sub>, suggesting a common neural substrate for AC thickness and N100 amplitude in SCZ<sub>spect</sub>. Further, we found positive associations between AC2 thickness and N100 amplitude in AH+ and between AC2 thickness and N100 amplitude in AH-. These findings may suggest a common neural substrate for AC2 thickness and N100 amplitude, ie, also related to AH.

Our findings of nominally smaller N100 amplitude in SCZ<sub>spect</sub> compared with HC are in line with previous studies.<sup>33,43-48</sup> It should be noted that we found nominally smaller N100 amplitude in AH-. While, to our knowledge, no previous study has investigated the association between N100 amplitude and lifetime history of AH in SCZ<sub>spect</sub>, 1 previous study reported lower N100 amplitude in a small group of patients with SCZ<sub>spect</sub> during active AH compared with periods where the same patients did not experience AH.<sup>61</sup> Past studies on the relationship between N100 amplitude and general psychopathology in SCZ<sub>spect</sub> have reported inconsistent findings,<sup>46</sup> and larger sample sizes are likely needed to disentangle the relationship between N100 amplitude and clinical characteristics in SCZ<sub>spect</sub>, including AH.

Further, while our findings of nominally thinner AC2 in SCZ<sub>spect</sub> and particularly driven by the AH+ groups compared with HC are partly in line with past studies.<sup>17,22</sup> In contrast to previous studies,<sup>17-19,22</sup> we did not find differences in AC1 thickness in AH+ compared with HC. This discrepancy could be explained by the relatively low number of AH+ participants ( $n = 17$ ). Furthermore, the sulcal-gyral pattern of the AC1 has high interindividual variability which can contribute to inconsistencies.<sup>14,74</sup> A clear consensus on the anatomical and functional definitions of the AC1 and AC2 would help facilitate comparison between studies.<sup>75</sup> The exact location of the AC1 is a subject of ongoing research.<sup>76</sup>

Follow-up analyses revealed nominally thinner PT in SCZ<sub>spect</sub> and significantly thinner PT in AH+ compared with HC, while HS thickness did not differ between patients and

controls (supplementary tables 6 and 8). Thus, our finding of nominally thinner AC2 in AH+ compared with HC was driven by reduced PT thickness. Further, we found a positive association between HS thickness and N100 amplitude and nominally positive association between PT thickness and N100 amplitude in AH+, but not in AH- (supplementary table 9). While N100 amplitude was only nominally smaller in AH+ compared with HC, these findings may suggest an association between thinner PT and smaller (less negative) N100 amplitude in AH+. The PT is involved in language and complex sound processing, and in pitch perception.<sup>14,77,78</sup> While previous studies have reported reduced bilateral PT gray matter volume in SCZ<sub>spect</sub> compared with controls,<sup>13,79,80</sup> few studies have examined the PT in SCZ<sub>spect</sub> patients with a history of AH. However, our findings of thinner PT in AH+ compared with HC are in line with 2 previous studies.<sup>17,81</sup> Although the neurobiological basis of AH is likely complex, our findings may suggest that thinner AC (particularly thinner PT) is a marker of elevated vulnerability for development of AH, a notion that would be consistent with previous postmortem evidence of altered AC2 morphology in SCZ<sub>spect</sub>.<sup>28,82</sup> However, altered AC1 morphology has also been reported in SCZ<sub>spect</sub><sup>83</sup> and reduced AC1 thickness in AH+.<sup>16</sup> Further, studies show altered AC gyrification in patients with SCZ<sub>spect</sub> and AH<sup>84</sup> and increased activation of AC1<sup>8,23,52-54</sup> and the AC2 (ie, PT)<sup>23,50,54,55</sup> during active AH. To our knowledge, no previous study has reported positive associations between AC thickness and N100 amplitude among SCZ<sub>spect</sub> or between AC2 thickness and N100 amplitude in AH+. Together, these findings might indicate a common neural substrate linking altered structure and function in the AC in these patients.

While we at this point can only speculate what neural substrate might explain the AC-N100 associations in SCZ<sub>spect</sub> and the AC2-N100 association in AH+, altered synaptic pruning might play a role. Synaptic pruning is essential for efficient communication between nerve cells involved in processing of auditory stimuli.<sup>85</sup> Altered synaptic pruning,<sup>86-89</sup> resulting in reduced dendritic spine density on cortical pyramidal neurons,<sup>90-93</sup> is part of the pathogenesis of SCZ<sub>spect</sub>. Reduced dendritic spine density<sup>31,32,90</sup> and reduced size of pyramidal cells in the AC,<sup>28,29</sup> both caused by altered synaptic pruning, may explain the nominally thinner AC2 in AH+. Further, reduced dendritic spine density on AC pyramidal cells (and interneurons) may result in desynchronized firing and a decreased summation of postsynaptic potentials resulting in reduced N100 amplitude in SCZ<sub>spect</sub>.<sup>94-96</sup> Further, excessive synaptic pruning in AC in SCZ<sub>spect</sub> may lead to impaired neural communication in cortical areas involved in auditory processing and thus result in increased risk for AH.<sup>97-99</sup> However, while the evidence for reduced dendritic density and altered pyramidal AC cell morphology in SCZ<sub>spect</sub> is strong, exactly how synaptic pruning relates to AC (particularly AC2) thickness, N100 amplitude, and AH in SCZ<sub>spect</sub> remains unknown. Other factors that may contribute to the structure-function relationships observed in SCZ<sub>spect</sub> and AH+ in our study include altered myelination and neurotransmitter levels in the AC and other brain regions connected to the AC. In particular, several lines of evidence indicate involvement of altered myelination in the pathogenesis of SCZ<sub>spect</sub><sup>100-111</sup> and AH.<sup>112,113</sup>

Some limitations should be considered when interpreting the current findings. First, the small sample of patients ( $n = 33$ ) may increase the risk of type 1 and 2 errors and the cross-sectional design limits our ability to determine whether structural alterations precede functional alterations. Longitudinal studies are needed to investigate this temporal

dimension. While our findings of a strong correlation between AC thickness and N100 amplitude in  $SCZ_{spect}$  suggesting a common neural substrate, we cannot conclude that AC thickness causes N100 amplitude reduction. Further, the way that we generated AEPs, using a small number of trials compared with what is typically recommended for AEPs, with long ISI of 9 seconds and with prepulse stimuli of 85 dB, is unusual. However, after visual inspection of AEPs, we found that the relative strong stimulus intensity and the long ISI did elicit robust and large-amplitude AEPs as described by others.<sup>67</sup>

In conclusion, we confirmed findings of nominally smaller N100 amplitude in  $SCZ_{spect}$  compared with HC and nominally thinner AC2 in AH+ compared with HC. In addition, we report positive associations between AC thickness and N100 amplitude in  $SCZ_{spect}$  (AC1 and AC2), in AH+ (AC2), and in AH- (AC1). These novel findings suggest that there might be a common neural substrate for AC thickness and N100 amplitude in  $SCZ_{spect}$ .

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

T.E. is a consultant to BrainWaveBank and Synovion and received speaker's honoraria from Lundbeck and Janssen Cilag. O.A.A. is a consultant to HealthLytix and received speaker's honoraria from Lundbeck. I.A. has received speaker's honoraria from Lundbeck. The other authors report no conflict of interest.

## Funding

This work was supported by the Research Council of Norway (223273, 274359, 249795, 248238), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073, 2017097, 2018037, 2018076), the Norwegian Extra Foundation for Health and Rehabilitation (2015/FO5146), the European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG 802998), and the Ebbe Frøland foundation and a research grant from Mrs Throne-Holst.

## References

1. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. *JAMA Psychiatry*. 2007; 64 (1) 19–28.
2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med*. 2005; 2 (5) e141 [PubMed: 15916472]
3. Hugdahl K. “Hearing voices”: auditory hallucinations as failure of top-down control of bottom-up perceptual processes. *Scand J Psychol*. 2009; 50 (6) 553–560. [PubMed: 19930254]
4. Hugdahl K. Auditory hallucinations: a review of the ERC “VOICE” project. *World J Psychiatry*. 2015; 5 (2) 193–209. [PubMed: 26110121]
5. Zielasek J, Gaebel W. [Schizophrenia and other primary psychotic disorders in ICD-11]. *Fortschr Neurol Psychiatr*. 2018; 86 (3) 178–183. [PubMed: 29621821]
6. Hugdahl K. Auditory hallucinations as translational psychiatry: evidence from magnetic resonance imaging. *Balkan Med J*. 2017; 34 (6) 504–513. [PubMed: 29019460]
7. Kompus K, Falkenberg LE, Bless JJ, et al. The role of the primary auditory cortex in the neural mechanism of auditory verbal hallucinations. *Front Hum Neurosci*. 2013; 7: 144. [PubMed: 23630479]
8. Kompus K, Westerhausen R, Hugdahl K. The “paradoxical” engagement of the primary auditory cortex in patients with auditory verbal hallucinations: a meta-analysis of functional neuroimaging studies. *Neuropsychologia*. 2011; 49 (12) 3361–3369. [PubMed: 21872614]

9. Petty RG, Barta PE, Pearlson GD, et al. Reversal of asymmetry of the planum temporale in schizophrenia. *Am J Psychiatry*. 1995; 152 (5) 715–721. [PubMed: 7726311]
10. Rossi A, Serio A, Stratta P, et al. Planum temporale asymmetry and thought disorder in schizophrenia. *Schizophr Res*. 1994; 12 (1) 1–7. [PubMed: 8018581]
11. Takahashi T, Sasabayashi D, Takayanagi Y, et al. Altered Heschl's gyrus duplication pattern in first-episode schizophrenia. *Schizophr Res*. 2021; 237: 174–181. [PubMed: 34536751]
12. Chance SA, Casanova MF, Switala AE, Crow TJ. Auditory cortex asymmetry, altered minicolumn spacing and absence of ageing effects in schizophrenia. *Brain*. 2008; 131 (Pt 12) 3178–3192. [PubMed: 18819990]
13. Kasai K, Shenton ME, Salisbury DF, et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. *Arch Gen Psychiatry*. 2003; 60 (8) 766–775. [PubMed: 12912760]
14. Kwon JS, McCarley RW, Hirayasu Y, et al. Left planum temporale volume reduction in schizophrenia. *Arch Gen Psychiatry*. 1999; 56 (2) 142–148. [PubMed: 10025438]
15. Hirayasu Y, McCarley RW, Salisbury DF, et al. Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients. *Arch Gen Psychiatry*. 2000; 57 (7) 692–699. [PubMed: 10891040]
16. Köse G, Jessen K, Ebdrup BH, Nielsen M. Associations between cortical thickness and auditory verbal hallucinations in patients with schizophrenia: a systematic review. *Psychiatry Res Neuroimaging*. 2018; 282: 31–39. [PubMed: 30384148]
17. Morch-Johnsen L, Nesvag R, Jorgensen KN, et al. Auditory cortex characteristics in schizophrenia: associations with auditory hallucinations. *Schizophr Bull*. 2017; 43 (1) 75–83. [PubMed: 27605526]
18. Chen X, Liang S, Pu W, et al. Reduced cortical thickness in right Heschl's gyrus associated with auditory verbal hallucinations severity in first-episode schizophrenia. *BMC Psychiatry*. 2015; 15: 152. [PubMed: 26149490]
19. Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, et al. Association between psychotic symptoms and cortical thickness reduction across the schizophrenia spectrum. *Cereb Cortex*. 2013; 23 (1) 61–70. [PubMed: 22291030]
20. Rimol LM, Nesvåg R, Hagler DJ, et al. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. *Biol Psychiatry*. 2012; 71 (6) 552–560. [PubMed: 22281121]
21. van Erp TGM, Walton E, Hibar DP, et al. Karolinska Schizophrenia Project. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry*. 2018; 84 (9) 644–654. [PubMed: 29960671]
22. van Swam C, Federspiel A, Hubl D, et al. Possible dysregulation of cortical plasticity in auditory verbal hallucinations—a cortical thickness study in schizophrenia. *J Psychiatr Res*. 2012; 46 (8) 1015–1023. [PubMed: 22626530]
23. Allen P, Modinos G, Hubl D, et al. Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neuro-chemistry and beyond. *Schizophr Bull*. 2012; 38 (4) 695–703. [PubMed: 22535906]
24. Modinos G, Costafreda SG, van Tol MJ, McGuire PK, Aleman A, Allen P. Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies. *Cortex*. 2013; 49 (4) 1046–1055. [PubMed: 22370252]
25. Palaniyappan L, Balain V, Radua J, Liddle PF. Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis. *Schizophr Res*. 2012; 137 (1–3) 169–173. [PubMed: 22341902]
26. Gaser C, Nenadic I, Volz HP, Büchel C, Sauer H. Neuroanatomy of “hearing voices”: a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. *Cereb Cortex*. 2004; 14 (1) 91–96. [PubMed: 14654460]
27. Parker EM, Sweet RA. Stereological assessments of neuronal pathology in auditory cortex in schizophrenia. *Front Neuroanat*. 2017; 11: 131. [PubMed: 29375326]
28. Sweet RA, Bergen SE, Sun Z, Sampson AR, Pierri JN, Lewis DA. Pyramidal cell size reduction in schizophrenia: evidence for involvement of auditory feedforward circuits. *Biol Psychiatry*. 2004; 55 (12) 1128–1137. [PubMed: 15184031]

29. Sweet RA, Pierri JN, Auh S, Sampson AR, Lewis DA. Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia. *Neuropsychopharmacology*. 2003; 28 (3) 599–609. [PubMed: 12629543]
30. Shelton MA, Newman JT, Gu H, et al. Loss of microtubule-associated protein 2 immunoreactivity linked to dendritic spine loss in schizophrenia. *Biol Psychiatry*. 2015; 78 (6) 374–385. [PubMed: 25818630]
31. Sweet RA, Henteleff RA, Zhang W, Sampson AR, Lewis DA. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. *Neuropsychopharmacology*. 2009; 34 (2) 374–389. [PubMed: 18463626]
32. Dorph-Petersen KA, Delevich KM, Marcisins MJ, et al. Pyramidal neuron number in layer 3 of primary auditory cortex of subjects with schizophrenia. *Brain Res*. 2009; 1285: 42–57. [PubMed: 19524554]
33. Force RB, Venables NC, Sponheim SR. An auditory processing abnormality specific to liability for schizophrenia. *Schizophr Res*. 2008; 103 (1–3) 298–310. [PubMed: 18571375]
34. Javitt Daniel C. Neurophysiological approaches to analyzing brain dysfunction in schizophrenia. *Psychiatr Ann*. 1993; 23 (3) 144–150.
35. Javitt DC. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. *Audiol Neurootol*. 2000; 5 (3–4) 207–215. [PubMed: 10859415]
36. Kantrowitz JT, Leitman DI, Lehrfeld JM, et al. Reduction in tonal discriminations predicts receptive emotion processing deficits in schizophrenia and schizoaffective disorder. *Schizophr Bull*. 2013; 39 (1) 86–93. [PubMed: 21725063]
37. Pekkonen E, Katila H, Ahveninen J, Karhu J, Huotilainen M, Tiihonen J. Impaired temporal lobe processing of preattentive auditory discrimination in schizophrenia. *Schizophr Bull*. 2002; 28 (3) 467–474. [PubMed: 12645678]
38. Näätänen R, Gaillard AWK, Mäntysalo S. Early selective-attention effect on evoked potential reinterpreted. *Acta Psychol (Amst)*. 1978; 42 (4) 313–329. [PubMed: 685709]
39. Näätänen R, Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. *Psychophysiology*. 1987; 24 (4) 375–425. [PubMed: 3615753]
40. Pantev C, Bertrand O, Eulitz C, et al. Specific tonotopic organizations of different areas of the human auditory cortex revealed by simultaneous magnetic and electric recordings. *Electroencephalogr Clin Neurophysiol*. 1995; 94 (1) 26–40. [PubMed: 7530637]
41. Pantev C, Hoke M, Lehnertz K, Lütkenhöner B, Fahrenndorf G, Stöber U. Identification of sources of brain neuronal activity with high spatiotemporal resolution through combination of neuromagnetic source localization (NMSL) and magnetic resonance imaging (MRI). *Electroencephalogr Clin Neurophysiol*. 1990; 75 (3) 173–184. [PubMed: 1689641]
42. Luck, SJ. *An Introduction to the Event-Related Potential Technique*. 2nd ed. The MIT Press; Cambridge, MA: 2014.
43. Brown KJ, Gonsalvez CJ, Harris AWF, Williams LM, Gordon E. Target and non-target ERP disturbances in first episode vs. chronic schizophrenia. *Clin Neurophysiol*. 2002; 113 (11) 1754–1763. [PubMed: 12417228]
44. Foxe JJ, Yeap S, Snyder AC, Kelly SP, Thakore JH, Molholm S. The N1 auditory evoked potential component as an endophenotype for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives, first-episode, and chronic schizophrenia patients. *Eur Arch Psychiatry Clin Neurosci*. 2011; 261 (5) 331–339. [PubMed: 21153832]
45. O'Donnell BF, Vohs JL, Hetrick WP, Carroll CA, Shekhar A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. *Int J Psychophysiol*. 2004; 53 (1) 45–55. [PubMed: 15172135]
46. Rosburg T, Boutros NN, Ford JM. Reduced auditory evoked potential component N100 in schizophrenia—a critical review. *Psychiatry Res*. 2008; 161 (3) 259–274. [PubMed: 18926573]
47. Salisbury DF, Collins KC, McCarley RW. Reductions in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia. *Schizophr Bull*. 2010; 36 (5) 991–1000. [PubMed: 19282472]


48. Wang B, Zartaloudi E, Linden JF, Bramon E. Neurophysiology in psychosis: the quest for disease biomarkers. *Transl Psychiatry*. 2022; 12 (1) 100. [PubMed: 35277479]
49. Shen CL, Chou TL, Lai WS, et al. P50, N100, and P200 auditory sensory gating deficits in schizophrenia patients. *Front Psychiatry*. 2020; 11: 868. [PubMed: 33192632]
50. Shergill SS, Brammer MJ, Williams SCR, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. *Arch Gen Psychiatry*. 2000; 57 (11) 1033–1038. [PubMed: 11074868]
51. Hugdahl K, Craven AR, Johnsen E, et al. Neural activation in the ventromedial prefrontal cortex precedes conscious experience of being in or out of a transient hallucinatory state. *Schizophr Bull*. 2022. sbac028
52. van de Ven VG, Formisano E, Roder CH, et al. The spatiotemporal pattern of auditory cortical responses during verbal hallucinations. *Neuroimage*. 2005; 27 (3) 644–655. [PubMed: 15978843]
53. Dierks T, Linden DEJ, Jandl M, et al. Activation of Heschl's gyrus during auditory hallucinations. *Neuron*. 1999; 22 (3) 615–621. [PubMed: 10197540]
54. Allen P, Laroï F, McGuire PK, Aleman A. The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. *Neurosci Biobehav Rev*. 2008; 32 (1) 175–191. [PubMed: 17884165]
55. Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. *Am J Psychiatry*. 2011; 168 (1) 73–81. [PubMed: 20952459]
56. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. *Arch Gen Psychiatry*. 2007; 64 (5) 521–529. [PubMed: 17485604]
57. Salisbury DF, Shafer AR, Murphy TK, Haigh SM, Coffman BA. Pitch and duration mismatch negativity and Heschl's gyrus volume in first-episode schizophrenia-spectrum individuals. *Clin EEG Neurosci*. 2020; 51 (6) 359–364. [PubMed: 32241184]
58. Javitt DC, Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. *Am J Psychiatry*. 2015; 172 (1) 17–31. [PubMed: 25553496]
59. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. *J Clin Invest*. 2009; 119 (4) 706–716. [PubMed: 19339762]
60. Liem F, Zaehle T, Burkhard A, Jancke L, Meyer M. Cortical thickness of supratemporal plane predicts auditory N1 amplitude. *Neuroreport*. 2012; 23 (17) 1026–1030. [PubMed: 23076120]
61. Hubl D, Koenig T, Strik WK, Garcia LM, Dierks T. Competition for neuronal resources: how hallucinations make themselves heard. *Br J Psychiatry*. 2007; 190: 57–62. [PubMed: 17197657]
62. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. *Arch Gen Psychiatry*. 1992; 49 (8) 624–629. [PubMed: 1637252]
63. Pedersen G, Hagtvet K, Karterud S. Generalizability studies of the Global Assessment of Functioning-Split version. *Compr Psychiatry*. 2007; 48: 88–94. [PubMed: 17145287]
64. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987; 13 (2) 261–274. [PubMed: 3616518]
65. Fischl B. FreeSurfer. *Neuroimage*. 2012; 62 (2) 774–781. [PubMed: 22248573]
66. Destrieux C, Fischl B, Dale A, Halgren E. Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. *Neuroimage*. 2010; 53 (1) 1–15. [PubMed: 20547229]
67. Pereira DR, Cardoso S, Ferreira-Santos F, et al. Effects of inter-stimulus interval (ISI) duration on the N1 and P2 components of the auditory event-related potential. *Int J Psychophysiol*. 2014; 94 (3) 311–318. [PubMed: 25304172]
68. Delorme A, Makeig S. EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. *J Neurosci Methods*. 2004; 134 (1) 9–21. [PubMed: 15102499]
69. Bigdely-Shamlo N, Mullen T, Kothe C, Su KM, Robbins KA. The PREP pipeline: standardized preprocessing for large-scale EEG analysis. *Front Neuroinform*. 2015; 9: 16. [PubMed: 26150785]

70. Pion-Tonachini L, Kreutz-Delgado K, Makeig S. ICLabel: an automated electroencephalographic independent component classifier, dataset, and website. *Neuroimage*. 2019; 198: 181–197. [PubMed: 31103785]
71. Graham SJ, Langley RW, Bradshaw CM, Szabadi E. Effects of haloperidol and clozapine on prepulse inhibition of the acoustic startle response and the N1/P2 auditory evoked potential in man. *J Psychopharmacol*. 2001; 15 (4) 243–250. [PubMed: 11769817]
72. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. Wickham, H, editor. Springer International Publishing; Cham: 2016. 189–201.
73. Thalheimer W, Cook S. How to calculate effect sizes from published research: a simplified methodology. *Work Learning Research*. 2009. 1–9.
74. Rademacher J, Caviness VS Jr, Steinmetz H, Galaburda AM. Topographical variation of the human primary cortices: implications for neuroimaging, brain mapping, and neurobiology. *Cereb Cortex*. 1993; 3 (4) 313–329. [PubMed: 8400809]
75. Barta PE, Petty RG, McGilchrist I, et al. Asymmetry of the planum temporale: methodological considerations and clinical associations. *Psychiatry Res*. 1995; 61 (3) 137–150. [PubMed: 8545498]
76. Poeppel, D. *The Human Auditory Cortex*. Springer; New York, NY: 2012.
77. Geschwind N, Levitsky W. Human brain: left-right asymmetries in temporal speech region. *Science*. 1968; 161 (3837) 186–187. [PubMed: 5657070]
78. Zheng ZZ. The functional specialization of the planum temporale. *J Neurophysiol*. 2009; 102 (6) 3079–3081. [PubMed: 19776362]
79. Takahashi T, Suzuki M, Zhou SY, et al. A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia. *Schizophr Res*. 2010; 119 (1–3) 65–74. [PubMed: 20051316]
80. Takahashi T, Wood SJ, Yung AR, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. *Arch Gen Psychiatry*. 2009; 66 (4) 366–376. [PubMed: 19349306]
81. Ratnanather JT, Poynton CB, Pisano DV, et al. Morphometry of superior temporal gyrus and planum temporale in schizophrenia and psychotic bipolar disorder. *Schizophr Res*. 2013; 150 (2–3) 476–483. [PubMed: 24012458]
82. Falkai P, Bogerts B, Schneider T, et al. Disturbed planum temporale asymmetry in schizophrenia. A quantitative post-mortem study. *Schizophr Res*. 1995; 14 (2) 161–176. [PubMed: 7710997]
83. Sweet RA, Bergen SE, Sun Z, Marcsisin MJ, Sampson AR, Lewis DA. Anatomical evidence of impaired feedforward auditory processing in schizophrenia. *Biol Psychiatry*. 2007; 61 (7) 854–864. [PubMed: 17123477]
84. Cachia A, Paillère-Martinot ML, Galinowski A, et al. Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. *Neuroimage*. 2008; 39 (3) 927–935. [PubMed: 17988891]
85. Blakemore S-J, Choudhury S. Development of the adolescent brain: implications for executive function and social cognition. *J Child Psychol Psychiatry*. 2006; 47 (3–4) 296–312. [PubMed: 16492261]
86. Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. *J Psychiatr Res*. 1994; 28 (3) 239–265. [PubMed: 7932285]
87. Sellgren CM, Gracias J, Watmuff B, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. *Nat Neurosci*. 2019; 22 (3) 374–385. [PubMed: 30718903]
88. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. *Science*. 2011; 333 (6048) 1456–1458. [PubMed: 21778362]
89. Feinberg IS. Caused by a fault in programmed synaptic elimination during adolescence? *J Psychiatr Res*. 1982; 17 (4) 319–334. [PubMed: 7187776]
90. Garey LJ, Ong WY, Patel TS, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. *J Neurol Neurosurg Psychiatry*. 1998; 65 (4) 446–453. [PubMed: 9771764]


91. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch Gen Psychiatry*. 2000; 57 (1) 65–73. [PubMed: 10632234]
92. Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. *Neuroscience*. 2013; 251: 90–107. [PubMed: 22546337]
93. Konopaske GT, Lange N, Coyle JT, Benes FM. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. *JAMA Psychiatry*. 2014; 71 (12) 1323–1331. [PubMed: 25271938]
94. Uhlhaas PJ, Singer W. Oscillations and neuronal dynamics in schizophrenia: the search for basic symptoms and translational opportunities. *Biol Psychiatry*. 2015; 77 (12) 1001–1009. [PubMed: 25676489]
95. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. *Nat Rev Neurosci*. 2010; 11 (2) 100–113. [PubMed: 20087360]
96. Hirano Y, Oribe N, Onitsuka T, et al. Auditory cortex volume and gamma oscillation abnormalities in schizophrenia. *Clin EEG Neurosci*. 2020; 51 (4) 244–251. [PubMed: 32204613]
97. de la Iglesia-Vaya M, Escartí M, Molina-Mateo J, et al. Abnormal synchrony and effective connectivity in patients with schizophrenia and auditory hallucinations. *Neuroimage Clin*. 2014; 6: 171–179. [PubMed: 25379429]
98. Ford JM, Roach BJ, Faustman WO, Mathalon DH. Synch before you speak: auditory hallucinations in schizophrenia. *Am J Psychiatry*. 2007; 164 (3) 458–466. [PubMed: 17329471]
99. Mulert C, Kirsch V, Pascual-Marqui R, McCarley RW, Spencer KM. Long-range synchrony of gamma oscillations and auditory hallucination symptoms in schizophrenia. *Int J Psychophysiol*. 2011; 79 (1) 55–63. [PubMed: 20713096]
100. Hao Y, Liu Z, Jiang T, et al. White matter integrity of the whole brain is disrupted in first-episode schizophrenia. *Neuroreport*. 2006; 17 (1) 23–26. [PubMed: 16361944]
101. Jørgensen KN, Nerland S, Norbom LB, et al. Increased MRI-based cortical grey/white-matter contrast in sensory and motor regions in schizophrenia and bipolar disorder. *Psychol Med*. 2016; 46 (9) 1971–1985. [PubMed: 27049014]
102. Kong L, Herold C, Stieltjes B, et al. Reduced gray to white matter tissue intensity contrast in schizophrenia. *PLoS One*. 2012; 7 (5) e37016 [PubMed: 22615876]
103. Szeszko PR, Ardekani BA, Ashtari M, et al. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. *Am J Psychiatry*. 2005; 162 (3) 602–605. [PubMed: 15741480]
104. Agartz I, Andersson JL, Skare S. Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. *Neuroreport*. 2001; 12 (10) 2251–2254. [PubMed: 11447344]
105. Bartzokis G. Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. *Front Biosci (Landmark Ed)*. 2011; 16 (7) 2695–2733. [PubMed: 21622204]
106. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. *Arch Gen Psychiatry*. 2003; 60 (5) 443–456. [PubMed: 12742865]
107. Du F, Cooper AJ, Thida T, Shinn AK, Cohen BM, Öngür D. Myelin and axon abnormalities in schizophrenia measured with magnetic resonance imaging techniques. *Biol Psychiatry*. 2013; 74 (6) 451–457. [PubMed: 23571010]
108. Wei W, Yin Y, Zhang Y, et al. Structural covariance of depth-dependent intracortical myelination in the human brain and its application to drug-naïve schizophrenia: a T1w/T2w MRI study. *Cereb Cortex*. 2022; 32 (11) 2373–2384. [PubMed: 34581399]
109. Wei W, Zhang Y, Li Y, et al. Depth-dependent abnormal cortical myelination in first-episode treatment-naïve schizophrenia. *Hum Brain Mapp*. 2020; 41 (10) 2782–2793. [PubMed: 32239735]
110. Kelly S, Jahanshad N, Zalesky A, et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Mol Psychiatry*. 2018; 23 (5) 1261–1269. [PubMed: 29038599]
111. Kubicki M, McCarley R, Westin CF, et al. A review of diffusion tensor imaging studies in schizophrenia. *J Psychiatr Res*. 2007; 41 (1–2) 15–30. [PubMed: 16023676]
112. Hubl D, Koenig T, Strik W, et al. Pathways that make voices: white matter changes in auditory hallucinations. *Arch Gen Psychiatry*. 2004; 61 (7) 658–668. [PubMed: 15237078]




113. Long P, Wan G, Roberts MT, Corfas G. Myelin development, plasticity, and pathology in the auditory system. *Dev Neurobiol.* 2018; 78 (2) 80–92. [PubMed: 28925106]




**Fig. 1.** Auditory evoked potential (AEP) from 12 randomly drawn  $SCZ_{spect}$  patients with schizophrenia spectrum disorders, including from 6 AH+, patients with  $SCZ_{spect}$  and AH, auditory hallucinations and 6 AH-, patients with  $SCZ_{spect}$  without AH.




**Fig. 2.**  
Auditory evoked potential (AEP) from 24 randomly drawn. HC, healthy controls.



**Fig. 3.** Auditory evoked potential (AEP) in (A) SCZ<sub>spect</sub>, patients with schizophrenia spectrum disorders ( $n = 33$ ), in (B) HC, healthy controls ( $n = 144$ ), in (C) AH+, patients with SCZ<sub>spect</sub> and AH, auditory hallucinations ( $n = 17$ ), and in (D) AH-, patients with SCZ<sub>spect</sub> without AH ( $n = 16$ ). The components of the AEP, the P50, the N100, and the P200. The AEP is not corrected for effect of age or sex.



**Fig. 4.** Association between thickness in AC1, primary auditory cortex (AC) and in AC2, secondary AC and in N100 amplitude in SCZ<sub>spect</sub>, patients with schizophrenia spectrum disorder (A and B) and in HC, healthy controls (C and D); est, estimate; se, standard error; *t*, *t*-value; *P*, *P*-value; \*, significant ( $P < .025$ ) association. AC thickness and N100 amplitude were set as dependent variables with age and sex as covariates. In SCZ<sub>spect</sub>, thickness in AC1 and AC2 was positively associated with N100 amplitude.



**Fig. 5.** Association between thickness in AC1, primary auditory cortex (AC) and AC2, secondary AC and N100 amplitude in AH+, patients with SCZ<sub>spect</sub>, schizophrenia spectrum disorder, with AH, auditory hallucinations (A and B) and in AH-, SCZ<sub>spect</sub> without AH (C and D); est, estimate; se, standard error; *t*, *t*-value; *P*, *P*-value; \*, significant ( $P < .025$ ) association. AC thickness and N100 amplitude were set as dependent variables with age and sex as covariates. In AH+, AC2 thickness was positively associated with N100 amplitude. In AH-, AC1 thickness was positively associated with N100 amplitude.

**Table 1**  
**Participant Characteristics**

	SCZ <sub>spect</sub> [n = 33]	AH+ [n = 17]	AH- [n = 16]	HC [n = 144]	SCZ <sub>spect</sub> vs HC	AH+ vs HC	AH- vs HC	AH+ vs AH-
					P- Value	P- Value	P- Value	P- Value
Women, n (%)	16 (48.48)	9 (52.94)	7 (43.75)	70 (48.61)	.99	.74	.71	.60
Age, year	29.96 (18.46– 54.06, 9.03)	30.14 (18.77– 54.06, 8.80)	29.77 (18.46– 47.64, 9.55)	32.94 (18.50– 45.58, 7.42)	.09	.22	.22	.91
Age of onset, year	24.50 (17–37, 5.18)	25.23 (17–37, 5.28)	23.64 (17–31, 5.16)	/	/	/	/	.46
DOI, year	4.13 (0–20.47, 5.35)	5.63 (1.01– 20.47, 6.82)	2.36 (0–7.14, 1.88)	/	/	/	/	.12
GAF-S	54.48 (38–85, 11.54)	52.82 (38–72, 9.03)	56.25 (38–85, 13.81)	/	/	/	/	.41
GAF-F	55.18 (35–85, 14.11)	56.12 (39–84, 12.16)	54.19 (35–85, 16.27)	/	/	/	/	.70
PANSS total	56.12 (33–91, 14.41)	52.18 (36–67, 9.57)	60.31 (33–91, 17.58)	/	/	/	/	.12
PANSS G	29.79 (18–47, 7.24)	27.65 (20–36, 5.35)	32.06 (18–47, 8.39)	/	/	/	/	.09
PANSS P	12.97 (7–24, 3.84)	12.71 (8–17, 2.80)	13.25 (7–24, 4.78)	/	/	/	/	.70
PANSS N	13.36 (7–25, 5.23)	11.82 (7–18, 3.66)	15 (7–25, 6.20)	/	/	/	/	.09
Antipsychotic drug use, DDD	1.01 (0.19–2.25, 0.58)	0.97 (0.25– 2.25, 0.59)	1.05 (0.19–2, 0.60)	/	/	/	/	.77

*Note:* Table 1 shows the demographics of the final study sample. SCZ<sub>spect</sub>, patients with schizophrenia spectrum disorders; AH+, SCZ<sub>spect</sub> with AH, auditory hallucinations; AH-, SCZ<sub>spect</sub> without AH; HC, healthy controls; n, number of women in each groups; %, percentage of women in each groups; age, mean age with range (min-max) and sd; Age of onset, age at first positive psychotic symptom in years (mean age of onset with range [min-max] and sd); DOI, duration of illness (mean DOI with range [min-max] and sd); GAF, Global Assessment of Function (mean GAF with range [min-max] and sd); GAF-S, GAF-symptoms; GAF-F, GAF-functioning; PANSS, Positive and Negative Syndrome Scale (mean PANSS with range [min-max] and sd); G, general; P, positive; N, negative; DDD, defined daily dose of antipsychotics (mean DDD with range [min-max] and sd); \*, significant *P*-value (*P* < .05) differences between groups; “/,” not relevant. Nine patients had missing information about age of onset and DOI. Sixteen had missing information about DDD. There were no significant differences between groups.

**Table 2**  
**Mean AC1 Thickness, AC2 Thickness, and N100 Amplitude in SCZ<sub>spect</sub> and HC**

	AC1 Thickness (mm) Mean (SE) [95% CI]	AC2 Thickness (mm) Mean (SE) [95% CI]		N100 Amplitude (Cz) (μV) Mean (SE) [95% CI]
SCZ <sub>spect</sub> [ <i>n</i> = 39]	2.58 (0.03) [2.54 – 2.63]	2.55 (0.02) [2.51–2.59]	SCZ <sub>spect</sub> [ <i>n</i> = 33]	12.19 (1.29) [9.65–14.74]
HC [ <i>n</i> = 146]	2.59 (0.01) [2.57–2.62]	2.60 (0.01) [2.58–2.62]	HC [ <i>n</i> = 144]	15.30 (0.61) [14.09–16.51]
SCZ <sub>spect</sub> vs HC	est = 0.01 se = 0.03 <i>t</i> = 0.27 <i>P</i> = .79 df = 181 Cohen's <i>d</i> = 0.06	est = 0.04 se = 0.02 <i>t</i> = 1.84 <i>P</i> = .07 df = 181 Cohen's <i>d</i> = 0.41	SCZ <sub>spect</sub> vs HC	est = 3.12 se = 1.43 <i>t</i> = 2.17 <i>P</i> = .03 df = 173 Cohen's <i>d</i> = 0.42

*Note:* Table 2 shows mean thickness, in AC1, primary auditory cortex and in AC2, secondary auditory cortex and mean N100 amplitude in SCZ<sub>spect</sub>, patients with schizophrenia spectrum disorder and in HC, healthy controls. Estimated marginal means were calculated using ANCOVA, where AC1 thickness, AC2 thickness, or N100 amplitude were set as dependent variables with age, sex and diagnosis as independent variables. Estimated marginal means are provided with SE (standard error of the mean) and 95% CI, confidence interval. In addition, table 2 shows differences in means between SCZ<sub>spect</sub> and HC. est, estimate; *t*, *t*-value; *P*, *P*-value; df, degree of freedom; \*, significant *P*-value (*P* < .017) difference between groups. We found no significant difference in AC thickness or N100 amplitude between groups. However, SCZ<sub>spect</sub> had nominally smaller N100 amplitude and thinner AC2 compared with controls.



**Table 3**  
**Mean AC1 Thickness, AC2 Thickness, and N100 Amplitude (Cz) in AH+, AH-, and HC**

	AC1 Thickness (mm) Mean (SE) [95% CI]	AC2 Thickness (mm) Mean (SE) [95% CI]		N100 Amplitude (Cz) ( $\mu$ V) Mean (SE) [95% CI]
AH+ [ <i>n</i> = 22]	2.58 (0.03) [2.51–2.64]	2.53 (0.03) [2.48–2.58]	AH+ [ <i>n</i> = 17]	13.48 (1.79) [9.95–17.00]
AH- [ <i>n</i> = 17]	2.60 (0.04) [2.52–2.67]	2.59 (0.03) [2.53–2.65]	AH- [ <i>n</i> = 16]	10.83 (1.84) [7.19–14.46]
HC [ <i>n</i> = 146]	2.59 (0.01) [2.57–2.62]	2.60 (0.01) [2.58–2.62]	HC [ <i>n</i> = 144]	15.30 (0.61) [14.09–16.51]
AH+ vs HC	est = 0.02 se = 0.04 <i>t</i> = 0.43 <i>P</i> = .67 df = 180 Cohen's <i>d</i> = 0.06	est = 0.07 se = 0.03 <i>t</i> = 2.31 <i>P</i> = .020 df = 180 Cohen's <i>d</i> = 0.53	AH+ vs HC	est = 1.83 se = 1.89 <i>t</i> = 0.97 <i>P</i> = .336 df = 172 Cohen's <i>d</i> = 0.24
AH- vs HC	est = -0.003 se = 0.04 <i>t</i> = -0.07 <i>P</i> = .94 df = 180 Cohen's <i>d</i> = 0.07	est = 0.01 se = 0.03 <i>t</i> = 0.29 <i>P</i> = .771 df = 180 Cohen's <i>d</i> = 0.08	AH- vs HC	est = 4.48 se = 1.95 <i>t</i> = 2.30 <i>P</i> = .020 df = 172 Cohen's <i>d</i> = 0.61
AH+ vs AH-	est = 0.02 se = 0.05 <i>t</i> = 0.36 <i>P</i> = .721 df = 180 Cohen's <i>d</i> = 0.13	est = 0.06 se = 0.04 <i>t</i> = 1.40 <i>P</i> = .165 df = 180 Cohen's <i>d</i> = 0.45	AH+ vs AH-	est = -2.65 se = 2.56 <i>t</i> = -1.04 <i>P</i> = .301 df = 172 Cohen's <i>d</i> = 0.35

*Note:* Table 3 shows mean thickness in AC1, primary auditory cortex, mean thickness in AC2, secondary auditory cortex and mean N100 amplitude in AH+, SCZ<sub>spect</sub>, patients with schizophrenia spectrum disorders, with AH, auditory hallucinations, in AH-, SCZ<sub>spect</sub> without AH and in HC, healthy controls. Estimated marginal means were calculated using ANCOVA, where AC1 thickness, AC2 thickness, or N100 amplitude were set as dependent variables with age, sex, and AH status (AH+, AH-, or HC) as independent variables. Estimated marginal means are provided with SE (standard error of the mean) and 95% CI, confidence interval. In addition, table 3 shows differences in means between AH+, AH-, and HC. est, estimate; *t*, *t*-value; *P*, *P*-value; df, degree of freedom; \*, significant *P*-value (*P* < .017) difference between groups. We found no significant difference in AC thickness or N100 amplitude between AH status. However, AH+ had nominally thinner AC2 while AH- had nominally smaller N1000 amplitude compared with HC.